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http://dx.doi.org/10n established technique to deliver a conformal dose
of radiation to patients with prostate cancer. The William Buckland Radiotherapy Center has been
performing high-dose-rate brachytherapy with external beam radiation treatment for prostate cancer
since 1998 and has an extensive prospective database on all patients treated. The purpose of this
analysis was to assess the risk of stricture formation and identify the predictive or causative factors.
METHODS AND MATERIALS: Three hundred fifty-four patients were treated between 1998
and 2008. Patients received one of three differing dose schedules: 20 Gy in four treatments
(20 Gy/4), 18 Gy/3, and 19 Gy/2 during three sequential time periods. NelsoneAalen cumulative
hazard modeling was used to estimate risk of events over time. Potential risk factors, including
dose, were identified and used in the analysis.
RESULTS: There were 45 patients who developed at least one stricture, an overall risk of 8.2% at
2 years. The 2-year risk of stricture formation was 3.4%, 2.3%, and 31.6% for 18 Gy/3, 20 Gy/4,
and 19 Gy/2, respectively. Most strictures occurred in the bulbomembranous urethra (50%) or
external sphincter region (33%). On multivariable analysis, the dose schedule used was the only
significant predictor for increased stricture formation.
CONCLUSIONS: In our patients, those who received 19 Gy/2 were at a significantly higher risk
of stricture formation. Most of these strictures were mild, requiring only one intervention but
a 2-year stricture risk of 31.6% was striking, and we have modified our protocol.  2013 American
Brachytherapy Society. Published by Elsevier Inc. All rights reserved.Keywords: Prostate cancer; High-dose-rate brachytherapy; Urethral stricture; Late toxicityIntroduction
Local disease control in intermediate- and high-risk local-
ized prostate cancer has been shown to have a dose response
(1e3) but at a cost of increased normal tissue toxicity (4, 5).
High-dose-rate brachytherapy (HDRB) in combination with
external beam radiotherapy (EBRT) is an established dose
escalation technique and offers outcomes at least compa-
rable with EBRT-only studies (6e8). HDRB in combinationmber 2011; received in revised form 16 February
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.1016/j.brachy.2012.03.004with EBRT has many advantages: it is more conformal than
EBRT alone, the high dose per fraction exploits a postulated
low a/b ratio of prostate cancer, and it reduces the overall
treatment time. The optimal dose schedule for HDRB in
combination with EBRT is yet to be established, but the dose
per fraction has been increased to attempt to improve disease
cure, reduce in-hospital time, and minimize discomfort for
the patient. On the other hand, side effects may also occur
as a result of such changes to the dose schedule. For example,
the high dose per fraction may also increase the risk of late
urethral toxicity. HDRB allows avoidance of structures
outside the prostate gland, but the dose is difficult to limit
and conform around the urethra, without reducing the pros-
tate dose. The purpose of this analysis was to identify the
stricture rate for patients over time; describe the strictures
observed; and to identify any factor, including dose deliv-
ered, that may be contributing to stricture risk.hed by Elsevier Inc. All rights reserved.
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We report on consecutive patients treated as part of a cura-
tive regimen that included EBRT and HDRB, from the
commencement of our program in November 1998 until
November 2008. All but 31 patients (8.8%) received
concurrent hormonemanipulation.Most patientswere at inter-
mediate or high risk (T category higher than T2a or prostate-
specific antigen level higher than 10 ng/mL or Gleason score
more than 6). Table 1 describes the patient characteristics.External beam radiotherapy
Fourteen patients received the EBRT component at
another center, for geographic reasons. The dose and frac-
tionation for these patients is documented but the technique
specifics were not. Ninety-six patients received the HDRB
before the EBRT and 258 received HDRB after EBRT,
depending on departmental logistics and theater list
availability.
The clinical target volume was the prostate only, with
departmental protocol margins added to create a planning
target volume. For the patients treated at the William Buck-
land Radiotherapy Center, a three-dimensional conformalTable 1
Disease characteristics
Age mean (range) 65 (46e84)
Mean PSA (range) 14.90 (1.0e77.7)
PSA group N (%)
#10 147 (41.5)
O10e20 135 (38.2)
O20 72 (20.3)
T stage N (%)
!T2 64 (18.0)
T2a 71 (20.1)
T2b 60 (17.0)
T2c 66 (18.6)
T2x 1 (0.3)
T3a 62 (17.5)
T3b 29 (8.2)
T4 1 (0.3)
Gleason score N (%)
!7 90 (26)
7 193 (54.5)
O7 69 (19.5)
NCCN risk group N (%)
Low 9 (2.5)
Intermediate 230 (65.0)
High 115 (32.5)
Median followup Mo (range)
Overall 59 (5e121)
20 Gy/4 103 (18e121)
18 Gy/3 67 (5e109)
19 Gy/2 21 (7e37)
16 Gy/2 40 (33e47)
PSA5 prostate-specific antigen; NCCN5National Comprehensive
Cancer Network.technique was used. No attempt was made to treat the pelvic
lymph nodes. The most common dose prescription was
46 Gy in 23 fractions (46 Gy/23), delivering 10 fractions
daily for a fortnight, prescribed at the International Commis-
sion on Radiation Units and Measurements prescription
point, using 18 MVphotons. Patients were given instructions
to have an empty rectum and ‘‘comfortably’’ full bladder for
the treatment. Gold fiducial markers were used with a daily
image-guided setup protocol since 2007.High-dose-rate brachytherapy
In all patients, the HDRBwas used as a ‘‘boost’’ in combi-
nation with EBRT. Since initiation of the HDRB program,
three progressive, escalated fractionation schedules were
used. From November 1998 to August 2000 a schedule of
20 Gy/4 was used. From September 2000 to June 2006, the
schedule changed to 18 Gy/3. From July 2006 until
November 2008, 19 Gy/2 was the standard. Two patients
planned to receive 18 Gy/3, but received one fraction of
6 Gy and a second fraction of 10 Gy (16 Gy/2). This was
because of the delays on Day 2, preventing a third fraction
being delivered in a timely fashion.
The technique has been previously described (8). Up until
July 2006, metal needles were used. Subsequently, plastic
catheters were used in an attempt to reduce trauma. These
needles or catheters were placed transperineally using trans-
rectal ultrasound and fluoroscopic imaging for guidance. The
needles or catheters were placed within the bladder lumen to
ensure adequate coverage of the prostate base. Before
September 2005, replanning was not routine. Since then,
patients were re-CT imaged on the simulator CT but only re-
planned if the needle movement was estimated to be greater
than 1 cm in the caudal direction. Since August 2008, all
patients were replanned for each fraction.
The identification of the apex in the planning images is
essential to ensure adequate coverage of the prostate. Before
September 2005, this was identified based on the planning
CT images. Since September 2005, a fiducial marker has
been placed at the apex under ultrasound guidance and used
as a reference to improve the identification of the apex on the
planning CT images.
The target volume for theHDRcomponentwas the prostate
with up to 6 mm in the cranialecaudal direction to account for
microscopic extension and potential needle movement.
Patients were planned using Plato (Nucletron, Veenendaal,
The Netherlands) planning software until October 2009, since
when the Nucletron Oncentra (Nucletron) planning system
was routinely used.
All fractions were given over one admission, at least
6 h apart. The HDRB was delivered by 192Ir source automat-
ically afterloaded with a microSelectron 192Ir (Nucletron).
As the prescribed dose changed over time, the dose to the
urethra was limited so that no more than 10% of the urethral
volume was to receive greater than 120% of the prescribed
dose (D10# 120%). The consequence of this is that the
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constraints remained constant.
Details on all patients were captured on a prospective
database, BrachyNet. No patients were lost to followup. At
each review, patients completed standard survey forms,
including International Prostate Symptom Score (IPSS),
rectal toxicity, and erectile dysfunction. Urethral stricture
events were collected prospectively. A stricture was docu-
mented if a patient underwent a surgical procedure for a stric-
ture (dilation or urethrotomy). This definition is equivalent to
Grade 2 or higher Common Terminology Criteria for
Adverse Events version 3 toxicity (9). The medical records
and surgical report, when available, were used to identify
the site of the stricture.
The risk of stricture was compared among the various
dose groups (the dose fractionation schedule 18 Gy/3,
20 Gy/4, 19 Gy/2, or 16 Gy/2). Potential confounding
factors were identified: urinary retention (defined as
requiring an in-dwelling catheter within 2 weeks following
the removal of the HDRB needles), previous transurethral
resection of prostate (TURP), order of the treatment (HDRB
before or after EBRT), the IPSS, the radiation oncologist, and
the urologist. The managing urologist was included because
the definition of stricture relies on a surgical procedure. This
makes the definition of stricture subjective, and potentially
the urologist’s intervention ‘‘threshold’’ may influence the
stricture rate.
Statistical analysis
The end point was date of first stricture. Time to stricture
formation was calculated from the date of HDRB implanta-
tion. Otherwise, the date for analysis was date of last fol-
lowup or date of death. Analysis was done using STATA
version 8. NelsoneAalen cumulative hazard modeling
was used to estimate risk over time. The statistical signifi-
cant of difference between hazard curves was calculated
using the log-rank test. Univariate and multivariate analysis
was performed using a Cox proportional regression model.
A two-sided p-value of less than 0.05 was considered
significant. Interactions between variables were tested by
separately adding factors into the model. All variables in
the univariate model were used for the multivariate anal-
ysis. A biologic model was also used to evaluate the total
dose received by the urethra.Fig. 1. Overall stricture risk over time for all patients. CI5 confidence
interval.Results
Three hundred fifty-four patients were treated with an
HDRB at William Buckland Radiotherapy Center (Table 1).
The median age was 65 years. Low-, intermediate-, or high-
risk nonmetastatic prostate adenocarcinoma made up respec-
tively 2.5%, 65%, and 19.5% of patients. Forty-three patients
received 20 Gy/4, 214 patients received 18 Gy/3, and
95 patients received 19 Gy/2. Two patients received 16 Gy/2
fractions as described above.In total, 45 patients had one or more strictures: 5 in the
20 Gy/4 group (11.6%), 20 in the 18 Gy/3 group (9.3%),
and 20 in the 19 Gy/2 group (21%). Neither of the two
patients who received 16 Gy developed a stricture. Thirteen
patients had a dilatation, whereas 32 had an urethrotomy as
initial management. The actuarial risk of stricture develop-
ment was 8.2% and 14% and at 24 and 48 months, respec-
tively (Fig. 1).
Table 2 describes the number of procedures and site of
stricture. Ten patients required more than one intervention,
7 had two procedures, 2 had three procedures, and 1 patient
required five urethrotomies. Strictures were generally ex-
traprostatic: 33.3% (15/45) had an apex/external sphincter
stricture, 35.6% (16) had a bulbar urethral stricture, and
13.3% (6) had a membranous stricture. Only 1 patient
had a prostatic urethral stricture and 1 patient had a late
meatal stricture.Dose group
The risk of stricture development was strikingly
different between the dose groups (Fig. 2). The estimated
cumulative risk of stricture at 2 years was 0%, 2.3%,
3.4%, and 31.6% for 16 Gy/2 (n5 2), 20 Gy/4, 18 Gy/3,
and 19 Gy/2 patients, respectively ( p!0.00001, log rank).
In a univariate analysis, the 19 Gy/2 group, urologist,
radiation oncologist, failed trial of void, implant year, and
biologic equivalent dose (BED) all predicted for increased
risk of stricture (Table 3). No significant association was
seen for IPSS, order of treatment, acute urinary retention,
or previous TURP. In a multivariable analysis, including
all factors, the 19 Gy/2 group and implant year were two
factors that remained predictive of an increased risk of
stricture formation (Table 4).Biologic urethral dose
The D10 (defined as the minimum dose received by the
‘‘hottest’’ 10% of the urethral volume) was calculated as an
Table 2
Site and frequency of stricture seen at cystoscopy
Parameters Frequency (%)
Number of procedures
1 35 (77.8)
2 7 (15.6)
3 2 (4.4)
5 1 (2.2)
Documented site of stricture
Apex/external sphincter 15 (33.3)
Bulbar urethra 16 (35.6)
Membranous urethra 6 (13.3)
Prostatic urethra 1 (2.2)
Bladder neck 2 (4.4)
Meatal urethra 1 (2.2)
Unknown 4 (8.9)
Table 3
Univariate Cox regression analysis
Factor HR p-Value 95% CI
Trial of void fail 2.1 0.034 1.1e4.1
Urologist 8 3.8 0.000 1.9e7.7
Radiation oncologist 3 2.3 0.012 1.2e4.5
Implant year 2007 7.4 0.000 3.3e16.2
Implant year 2008 3.4 0.033 1.1e10.3
BED total 1.1 0.001 1.1e1.2
20/4 Gy dose group 0.4 0.001 0.2e0.7
19/2 Gy dose group 10.9 0.000 5.0e23.7
TURP 1.37 0.42 0.6e2.9
Acute urinary retention 1.72 0.12 0.9e3.4
IPSS 0.97 0.18 0.9e1.0
HDRB before EBRT 0.83 0.60 0.4e1.7
HR5 hazard ratio; CI5 confidence interval; BED5 biologic equiva-
lent dose; TURP5 transurethral resection of the prostate; IPSS5 Interna-
tional Prostate Symptom Score; HDRB5 high-dose-rate brachytherapy;
EBRT5 external beam radiation therapy.
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with an assumed a/b of 3 Gy for prostate cancer and late
effects. This dose included the external beam prescribed dose
(It was assumed that the urethra received the total prescribed
EBRT dose). The mean urethral D10 (BED2Gy) was 91.4 Gy
in patients with a stricture compared with 87.0 Gy in those
with no stricture ( p!0.0017, t test). However, the D10
(BED2Gy) was significantly higher in the 19 Gy/2 dose group
compared with all others (Table 5). No correlation was seen
within dose groups between D10 and stricture risk.Discussion
A urethral stricture is a recognized late effect of any pros-
tate cancer therapy (10). It appears that stricture rates are
higher in HDRB compared with low-dose-rate brachyther-
apy (LDRB) and EBRT (11), and this may imply a BED
response. For example, Mohammed et al. (11) analyzed
1903 patients who received EBRT, LDRB, or HDRB. The
stricture risk was significantly higher in HDRB patients
compared with EBRT and LDRB, 11%, 2%, and 4%
respectively.Fig. 2. Stricture risk, by the dose group.We have reported a large patient database, with prospec-
tive gathering of stricture occurrence as well as other
toxicity in the followup for HDRB used as a boost to EBRT.
In our patients, the overall crude stricture incidence was
12.7% and is comparable with other series (12, 13). A con-
cerning predictive factor seen in this study was the fraction-
ation schedule and the BED delivered to the urethra,
measured by the D10. The patients in the 19 Gy/2 group
had a significantly higher risk of developing a stricture
compared with the other fractionation schedules, and we
have subsequently changed our protocol to 18 Gy/3. The
D10 for urethra predicted stricture development, but this
correlated directly to the fractionation schedule. The other
predictive factor, on multivariate analysis, was a prostate-
specific antigen level lower than 10 ng/mL. These patients
had a significantly lower stricture rate.
This dose correlation has been reported by other groups.
Sullivan et al. (13) reported on the late stricture risk in 474
patients treated with HDRB, either as a boost or as a mono-
therapy. The EBRT dose used was comparable with ours,
but the HDRB schedules consisted of 16e20 Gy/4 or
19.5 Gy/3. They found a 6-year rate of 11.2% for those
who received an HDRB boost to EBRT. They also reported
an increased stricture rate using a high-dose single-fraction
HDRB with no EBRT. In this group, the actuarial 3-year
rate was 15.3%. Pellizzon et al. (14) reported a series of
108 men with a median followup of 4 months who received
EBRT and HDRB boost of 16e20 Gy/4. At 5 years, theTable 4
Multivariable Cox proportional regression analysis for stricture risk
Factor HR p-Value 95% CI
Year of implant 1.2 0.041 1.0e1.5
PSA!10 0.47 0.025 0.3e0.9
19/2 Gy dose group 5.2 0.004 1.7e16.3
HR5 hazard ratio; CI5 confidence interval; PSA5 prostate-specific
antigen.
Table 5
Urethral D10 (BED2Gy) for each dose group
Dose group Mean urethral D10 (BED2Gy) Standard deviation Frequency
18 Gy/3 82.3 1.2 206
20 Gy/4 81.5 1.2 27
19 Gy/2 100.7 1.9 95
16 Gy/2 86.2 0.8 2
Total 87.6 8.5 330
BED2Gy5 biologic equivalent dose in 2 Gy fractions, using an a/b ratio
of 3 Gy for late effects.
Note: Data are available only for 330 patients. Initial 24 patients did
not have this variable documented.
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the actuarial outcomes are comparable with ours for
18e20 Gy/3e4.
In contrast, many studies, using biologically similar
schedules to ours either do not report strictures (15e18) or
report only a crude rate of less than 12% (11, 13, 19e22).
For example, recentlyHsu et al. (18) reported the preliminary
results of Radiation Therapy Oncology Group 0321 study.
One hundred twenty-nine patients underwent a 45 Gy EBRT
with an HDRB boost of 19 Gy/2. Although the followup
frame is limited, they reported actuarial late genitourinary
toxicity of less than 3% at 18 months. However, they neither
report strictures as a separate toxicity nor is it clear that the
data forms used would capture these episodes with certainty.
We were able to document the site of stricture in the vast
majority of patients. Consistent with the literature, 43 of 45
strictures were at, or below, the apex. Only 1 patient had an
intraprostatic stricture and 1 had a bladder neck contracture.
Sullivan et al. (13) reported almost identical pattern of stric-
ture positions, with 35 of 38 strictures seen in the bulbomem-
branous urethra. The position of strictures, at or below the
apex, is suggestive of dose sensitivity in this anatomic region.
In a retrospective analysis, Mohammed et al. (11) found that
the risk of stricturewas significantly associated with a bulbo-
membranous urethral ‘‘hotspot.’’ In this current analysis, we
have not measured dose in the bulbar/apex region. However,
a higher urethralD10 correlated to the risk of stricture forma-
tion. Therefore, the acceptable maximum to the urethra has,
as an absolute value, increasedwith each change in dose frac-
tionation. If this maximal region is in the apex or bulbar
region, any caudal needle movement may increase the stric-
ture risk.
In HDRB, the potential for caudal needle movement is
well documented. It is conceivable that the apex/bulbomem-
branous urethra is getting a higher dose owing to the needle
or catheter shift. However, since September 2005, and the
entire time of delivering 19 Gy/2, we have initiated prefrac-
tion CT imaging to assess caudal movement and replanning
if caudal movement was greater than 1 cm. In fact, since
August 2008, replanning the second fraction with
CT imaging became standard. It seems unlikely that caudal
needle movement has any causal relationship with strictures,
given the strictures occurred when caudal movement wasless likely. However, we did not analyze the site of the
urethral hot spot. Conceivably, an apical ‘‘hot’’ region, asso-
ciated with caudal movement, is a plausible explanation for
stricture formation at or below the apex.
Many other factors have been implicated in increasing
the risk for urethral stricture following HDRB, yet few
are consistent. A TURP before brachytherapy has been
commonly associated with stricture formation inmany series
(13, 23e25). In this current series, there was no correlation
between a stricture and previous TURP.Other clinical factors
such as age, hypertension, and baseline IPSS score have been,
less consistently, implicated as predictors of stricture forma-
tion (13, 14, 26).
One of the difficulties in reporting stricture rate is its
very definition as a late toxicity. Using the Common Termi-
nology Criteria for Adverse Events version 3, the definition
of a stricture as an adverse event is dependent on a urological
intervention, such as dilatation or urethrotomy. Different
urologists may have a lower threshold to investigate and
intervene in patients presenting with urological obstructive
symptoms. The referral pathways and urologist involvement
in followup would also influence the diagnosis of stricture.
We think it is possible that the true stricture rate is underesti-
mated owing to this definition and the practicalities of
capturing these incidents.
In addition, this definition does not provide any useful
grading for the severity of a stricture adverse event. A surro-
gate for severitymay be to look at the type of procedure or the
number of repeat procedures. The type of procedure used is
subjective and depends on the urologist’s preference and
skills, rather than a true indicator of severity. Although repeat
procedures are also subject to the urologist’s intervention
threshold, it is a reasonable marker of stricture severity. In
our study, 10 (22%) patients needed a repeat procedure and
of these only 3 (6.7%) needed more than two procedures.
Our rate of repeat procedures is similar to other LDR and
HDR series (13, 26). Many patients, who develop urethral
strictures, learn self-catheterization. This procedure may
impact on quality of life, more so than a one-off urethrotomy.
However, we did not capture the self-catheterization rate as
reliably as urethrotomy/dilatation.
Our series has captured all stricture development prospec-
tively on an electronic database since the inception of our
program, and we have high rates of sustained personal follow-
up contact with patients.We believe thatwe have not therefore
had any change in the likelihood of case ascertainment. We
believe this increase is real, not a procedural or structural arti-
fact. Although other factors have changed over time (specific
urologist participation, replanning, and a change from steel
needles to plastic catheters), we believe themultivariable anal-
ysis and consideration of biologically plausible mechanisms
point to the change to 19 Gy/2 as the most likely explanation
for the change we have observed. Our dose schedule,
constraints, and techniques are very similar to many other
groups, and it is possible that the stricture rate at higher doses
per fraction is widely underappreciated because followup in
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manifested, or because as discussed, the definitions and survey
instruments do not reliably capture these stricture events.Conclusion
HDRB as a boost to EBRT is a proven technique for
dose escalation in prostate cancer. However, there may be
a higher risk of late urethral stricture depending on the
dose-fractionation schedule used. The risk for a stricture,
in this large series, was most strongly related to change
of the fractionation schedule to 19 Gy/2 and consequen-
tially a higher urethral D10. As it turns out, most patients
diagnosed with a stricture only needed to undergo a single
procedure. Brachytherapy-related urethral strictures may be
underreported and may not be easily routinely captured in
toxicity data. Unlike most research reports, we hope our
results are not easily reproduced, and are concerned they
might be, inadvertently. Our department has changed the
fractionation to 18 Gy/3.Acknowledgments
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